PUBLISHER: The Business Research Company | PRODUCT CODE: 1951592
PUBLISHER: The Business Research Company | PRODUCT CODE: 1951592
Cell therapy involves the replacement or repair of damaged tissues and/or cells through the transplantation of human cells. Various types of cells can be employed in treatments for numerous diseases and disorders, supported by advanced technologies, innovative products, and creative approaches. In this therapy, patients receive live cells through injection, grafting, or implantation to achieve a therapeutic effect.
The primary techniques in cell therapy include stem cell therapy, cell vaccines, adoptive cell transfer (ACT), fibroblast cell therapy, and chondrocyte cell therapy. Stem cell therapy, also called regenerative medicine, utilizes stem cells or their derivatives to trigger the healing of diseased, damaged, or injured tissues. Different therapy types include allogeneic and autologous therapies, which are applied in various fields such as oncology, cardiovascular disease (CVD), orthopedics, wound healing, and more.
Tariffs have introduced both challenges and opportunities for the cell therapy market by affecting the import and export of human cells, reagents, and specialized manufacturing equipment. Increased costs for critical raw materials and delays in supply chains have particularly impacted segments like stem cell therapy and CAR T-cell therapy, with North America and Europe experiencing the most disruption due to reliance on imported biologics. Some companies are leveraging tariffs to localize production and invest in domestic cell manufacturing facilities, potentially improving resilience and innovation in the long term.
The cell therapy market research report is one of a series of new reports from The Business Research Company that provides cell therapy market statistics, including cell therapy industry global market size, regional shares, competitors with a cell therapy market share, detailed cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cell therapy industry. This cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cell therapy market size has grown rapidly in recent years. It will grow from $16.87 billion in 2025 to $19.31 billion in 2026 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to high cost of autologous therapies, limited donor availability, lack of standardized manufacturing, early-stage clinical trial success, rising incidence of chronic diseases.
The cell therapy market size is expected to see rapid growth in the next few years. It will grow to $32.48 billion in 2030 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to advancements in gene editing, automation in cell manufacturing, growing investment in cell therapy startups, increasing demand for regenerative medicine, expanding application across oncology and cvd. Major trends in the forecast period include personalized cell therapy development, allogeneic therapy advancements, improved cell storage & transportation, regulatory & compliance innovations, emerging clinical applications.
The rising prevalence of chronic diseases has supported the growth of the cell therapy market. According to the US Centers for Disease Control and Prevention (CDC), a chronic disease is a condition lasting one year or more that requires medical attention, limits daily activities, or both, and includes heart disease, cancer, diabetes, and Parkinson's disease. Stem cells offer potential benefits for patients with spinal cord injuries, type 1 diabetes, Parkinson's disease, heart disease, cancer, and osteoarthritis. For example, in July 2024, the CDC reported significant updates on public health initiatives: over 944,800 Americans die annually from heart disease or stroke, representing more than one-third of all deaths; 1.7 million are diagnosed with cancer each year, with over 600,000 fatalities, making it the second leading cause of death; more than 38 million Americans have diabetes, with 98 million adults prediabetic; and obesity affects 20% of children and 42% of adults, increasing the risk of type 2 diabetes, heart disease, and certain cancers. This growing prevalence of chronic diseases has driven demand for cell therapies, contributing to market expansion.
Key players in the cell therapy market are developing next-generation, multi-targeted therapies backed by strong early-stage clinical data to improve treatment outcomes and address unmet needs in complex cancers. For instance, in June 2025, Johnson & Johnson, a US-based pharmaceutical company, reported promising initial results from its Phase 1b study of JNJ-4496, a dual-targeting CAR T-cell therapy designed to bind both CD19 and CD20 in relapsed or refractory large B-cell lymphoma. Early data presented at the 2025 EHA Congress showed 75-80% complete responses at the recommended Phase 2 dose, with no Grade 3-4 cytokine release syndrome. The therapy demonstrated encouraging safety, manageable neurotoxicity, and robust activity even in heavily pretreated patients, highlighting the potential of next-generation dual-targeting CAR T therapies and reinforcing Johnson & Johnson's commitment to advancing innovative treatments for B-cell malignancies.
In August 2023, Eli Lilly and Company, a US-based pharmaceutical firm, acquired Sigilon Therapeutics for $34.6 million. This acquisition allows Lilly to strengthen its research and development in encapsulated cell therapies, specifically targeting Type 1 diabetes with its lead candidate, SIG-002, bolstering its position in the diabetes treatment market. Sigilon Therapeutics is a US-based biotechnology company focused on developing innovative cell therapies.
Major companies operating in the cell therapy market are Stempeutics Research Pvt. Ltd., Osiris Therapeutics Inc., Vericel Corporation, AlloSource, Anterogen Co. Ltd., MediPost Co. Ltd., Pharmicell Co. Ltd., Corestem Inc., Stemedica Cell Technologies Inc., Adaptimmune Therapeutics plc, Mesoblast Ltd., Cell Medica Ltd., Cellerant Therapeutics Inc., Kolon TissueGene Inc., Athersys Inc., Forticell Bioscience Inc., Bone Therapeutics, Holostem Terapie Avanzate S.r.l, Fibrocell Science Inc., AlloCure Inc., TiGenix NV, Cells for Cells, Cellular Biomedicine Group Inc.
North America was the largest region in the cell therapy market in 2025. The regions covered in the cell therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cell therapy market includes revenues earned by entities by enhancing the growth of new healthy skin tissue and enhancing collagen production. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cell Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses cell therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for cell therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cell therapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.